TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18555864

Group type: EXPERIMENTAL
Intervention: THA
Number of subjects: 210

Group type: COMPARATOR
Intervention: THR
Number of subjects: 210
Study: 15768425

Group type: EXPERIMENTAL
Intervention: Continuous 100 microT(rms) 50 Hz MF exposure
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bright light (5000 lux) exposure
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 18
Study: 16737149

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 x 500 mg) with omeprazole (2 x 20 mg) and clarithromycin (2 x 500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metronidazole (2 x 500 mg) with omeprazole (2 x 20 mg) and clarithromycin (2 x 500 mg)
Number of subjects: 0
Study: 11074536

Group type: EXPERIMENTAL
Intervention: alpha-interferon (3 mU s.c. 3 x weekly)
Number of subjects: 172

Group type: COMPARATOR
Intervention: dexamethasone (20 mg/m2 p.o. each morning for 4 days)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 172

Group type: COMPARATOR
Intervention: dexamethasone
Number of subjects: 172
Study: 8832444

Group type: EXPERIMENTAL
Intervention: Sevoflurane (2% initial target concentration, increments of 0.25%)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 65% Nitrous Oxide (N2O)
Number of subjects: 53
Study: 1413981

Group type: EXPERIMENTAL
Intervention: Diuretic and possibly a beta-blocker or reserpine (active treatment group)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 4
Study: 3911479

Group type: EXPERIMENTAL
Intervention: Intramuscular stanozolol, 50 mg on the preoperative day (n = 23)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral stanozolol, 10 mg/day for 2 weeks before and 1 week after operation (n = 11)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 60
Study: 31331587

Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM) 6g daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30775426

Group type: EXPERIMENTAL
Intervention: roflumilast 500 ug daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 26912342

Group type: EXPERIMENTAL
Intervention: Implementation support consisting of US Center for Disease Control's Replicating Effective Programs strategy supplemented by external and internal implementation facilitation support.
Number of subjects: 765

Group type: COMPARATOR
Intervention: Dissemination of materials plus technical assistance conference calls.
Number of subjects: 765
Study: 25807670

Group type: EXPERIMENTAL
Intervention: Warm saline mouth rinse (gargled 6 times daily)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no mouth rinse instructions)
Number of subjects: 160
Study: 23546629

Group type: EXPERIMENTAL
Intervention: Bufei Yishen Granule combined with Shufei Tie acupoint sticking therapy
Number of subjects: 244
Study: 20884928

Group type: EXPERIMENTAL
Intervention: Mucoadhesive disks (OraMoist) applied three times daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo mucoadhesive disks applied three times daily
Number of subjects: 27
Study: 17884837

Group type: EXPERIMENTAL
Intervention: Tailored behavioral support intervention (telephone counseling sessions with newsletters)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control condition (quarterly mailings)
Number of subjects: 53
Study: 15669885

Group type: EXPERIMENTAL
Intervention: Sertraline 50 to 150 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12668540

Group type: EXPERIMENTAL
Intervention: Intervention group received confidential profiles of benzodiazepine prescription use and educational bulletins for 6 months.
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Control group received feedback and educational bulletins about first-line antihypertension drug prescribing.
Number of subjects: 1624
Study: 10606284

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No androgen deprivation
Number of subjects: 0
Study: 7851595

Group type: EXPERIMENTAL
Intervention: Strict morphology analysis 1 month before the beginning of IUI following the criteria of Kruger et al.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Strict morphology analysis with morphology index > 10%
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Strict morphology analysis in pure male infertility group
Number of subjects: 74
Study: 1780738

Group type: COMPARATOR
Intervention: Dopamine (7 micrograms/kg b.w./min)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Insulin-Dopamine (7 IU/kg + dopamine)
Number of subjects: 19
Study: 6780974

Group type: EXPERIMENTAL
Intervention: Mannitol irrigation (group II, n = 12)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-irrigated (group I, n = 16)
Number of subjects: 28
Study: 31488371

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Periodic repolarisation dynamics of 7.5 deg or higher
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Periodic repolarisation dynamics less than 7.5 deg
Number of subjects: 1371

Group type: COMPARATOR
Intervention: Control group (conservative treatment)
Number of subjects: 1371
Study: 28834830

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation using absorbable mesh plates and screws
Number of subjects: 55

Group type: COMPARATOR
Intervention: Orbital floor reconstruction
Number of subjects: 55
Study: 25648791

Group type: EXPERIMENTAL
Intervention: Use of covariates in randomization
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Reporting of covariates
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Significance tests of baseline balance
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Adjustment for baseline measures of primary outcome
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Analysis adjusting for all covariates
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Adjusted analysis of primary outcome
Number of subjects: 300
Study: 24261335

Group type: EXPERIMENTAL
Intervention: Personal, social, and environmental factors influencing physical activity
Number of subjects: 2415
Study: 21380992

Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM) with positive end-expiratory pressure (PEEP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional ventilation without LRM
Number of subjects: 20
Study: 19736895

Group type: EXPERIMENTAL
Intervention: The needle catcher surgical instrument
Number of subjects: 20
Study: 17413099

Group type: EXPERIMENTAL
Intervention: Higher-protein (HP) group; 1.2 g protein . kg(‐1) . d(‐1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lower-protein (LP) group; 0.9 g protein . kg(‐1) . d(‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 36
Study: 15492337

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg twice daily
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Tamsulosin, 0.4 mg once daily
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combination of ciprofloxacin and tamsulosin
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 11444447

Group type: EXPERIMENTAL
Intervention: Epidural 2% lidocaine (0.08 mL.cm(‐1)) followed by iv normal saline and then propofol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Epidural normal saline followed by iv 2% lidocaine (0.05 mL.kg(‐1)) then propofol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epidural normal saline followed by iv normal saline then iv propofol
Number of subjects: 120
Study: 10195235

Group type: EXPERIMENTAL
Intervention: REMUNE (gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant)
Number of subjects: 0
Study: 7641247

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2666452

Group type: EXPERIMENTAL
Intervention: sulindac 200 mg twice daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 359251

Group type: EXPERIMENTAL
Intervention: 250 mg diflunisal twice daily (increased by 250 mg daily for some patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 250 mg naproxen twice daily (increased by 250 mg daily for some patients)
Number of subjects: 20
Study: 30614013

Group type: EXPERIMENTAL
Intervention: AFXL-rhEGF
Number of subjects: 24

Group type: COMPARATOR
Intervention: AFXL-Aloe
Number of subjects: 24
Study: 29785496

Group type: EXPERIMENTAL
Intervention: Bareback sexually explicit media (SEM) consumption
Number of subjects: 659

Group type: COMPARATOR
Intervention: PrEP disclosure
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Perceived partner attractiveness
Number of subjects: 659
Study: 28771627

Group type: EXPERIMENTAL
Intervention: Azithromycin (5 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 24424433

Group type: EXPERIMENTAL
Intervention: Diabetic patients (70 participants)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Healthy control subjects (40 participants)
Number of subjects: 110
Study: 23275453

Group type: EXPERIMENTAL
Intervention: Soy milk (n=16)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Dairy milk (n=15)
Number of subjects: 31
Study: 19778663

Group type: EXPERIMENTAL
Intervention: PON-1 glutamine isotype at codon 192
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: PON-1 methionine isotype at codon 55
Number of subjects: 793

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 793
Study: 17297383

Group type: EXPERIMENTAL
Intervention: Rifalazil 25 mg
Number of subjects: 170

Group type: COMPARATOR
Intervention: Azithromycin 1.0 g
Number of subjects: 170
Study: 15385119

Group type: EXPERIMENTAL
Intervention: 0.3 mg/m2 daily for 5 days every 3 weeks (Arm A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 2.1 mg/m2 weekly for 3 weeks out of 4 (Arm B)
Number of subjects: 57
Study: 11256875

Group type: EXPERIMENTAL
Intervention: Education class on osteoporosis
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Education plus BMD testing
Number of subjects: 508

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 508
Study: 9789709

Group type: EXPERIMENTAL
Intervention: Hallucinators (n = 14)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-hallucinating controls (n = 21)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lanthony D‐15 (LD) test
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vis tech tables (VT) at 1.5 cycles per degree
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vis tech tables (VT) at 3 cycles per degree
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Monocular Pelli‐Robson test (PR)
Number of subjects: 35
Study: 8005182

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg tds)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg tds)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oxazepam (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methyldopa (250 mg tds)
Number of subjects: 10
Study: 2810238

Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dilation and massage
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cryosurgery (after crossover)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cryosurgery (select group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dilation and massage (select group)
Number of subjects: 24
Study: 31863406

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy plus migraine education (ACT-ED)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Support plus migraine education (S-ED)
Number of subjects: 136
Study: 30858518

Group type: EXPERIMENTAL
Intervention: Lithium (n = 18)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 34
Study: 29092982

Group type: EXPERIMENTAL
Intervention: Single bolus of 20 mg/kg IV TXA before incision (group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Single bolus followed by a second bolus of 1 g IV TXA three hours later (group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Single bolus followed by two boluses of 1 g IV TXA three and six hours later (group C)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 150
Study: 25096409

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (SET)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Direct communication (non-story)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-story communication
Number of subjects: 41

Group type: COMPARATOR
Intervention: Story communication
Number of subjects: 41
Study: 23200803

Group type: EXPERIMENTAL
Intervention: Noncardioselective β blockers
Number of subjects: 2670

Group type: EXPERIMENTAL
Intervention: Cardioselective β blockers
Number of subjects: 2670
Study: 21331773

Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional PCNL
Number of subjects: 131
Study: 18381090

Group type: EXPERIMENTAL
Intervention: Hematologist/Oncologist involvement in diagnosis and management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support for clinical trials and drug development
Number of subjects: 0
Study: 16434531

Group type: EXPERIMENTAL
Intervention: 2-octylcyanoacrylate (OCA)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Skin staples
Number of subjects: 187

Group type: COMPARATOR
Intervention: Subcuticular suture (monocryl)
Number of subjects: 187
Study: 12761013

Group type: EXPERIMENTAL
Intervention: Nalbuphine (4 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (4 mL normal saline)
Number of subjects: 240
Study: 11061604

Group type: EXPERIMENTAL
Intervention: Cisplatin-etoposide-based chemotherapy
Number of subjects: 332
Study: 9052565

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (SUPEX) for 12 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Home-based exercise program (HOMEX) for 12 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups (SUPEX and HOMEX)
Number of subjects: 55
Study: 7913674

Group type: EXPERIMENTAL
Intervention: Longitudinal data with autocorrelation structure
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Different values of the correlation parameters, gamma and theta
Number of subjects: 2
Study: 3292338

Group type: EXPERIMENTAL
Intervention: Tru-Cut needle
Number of subjects: 1192
Study: 31879194

Group type: EXPERIMENTAL
Intervention: Microelectrodes coupled to a 4 MHz generator in cutting mode
Number of subjects: 22

Group type: COMPARATOR
Intervention: Microelectrodes coupled to a 4 MHz generator in coagulation mode
Number of subjects: 22
Study: 31300951

Group type: EXPERIMENTAL
Intervention: Elastomeric sealant (Group S)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 81
Study: 31219248

Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin FDC tablet (5 mg/50 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin FDC tablet (5 mg/100 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin FDC tablet (15 mg/50 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin FDC tablet (15 mg/100 mg)
Number of subjects: 19
Study: 28543263

Group type: EXPERIMENTAL
Intervention: 3 g mesalazine once daily (SAG-37)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo (SAG-37)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: 1.5 g mesalazine once daily (SAG-51)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: 3 g mesalazine once daily (SAG-51)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo (SAG-51)
Number of subjects: 675
Study: 25873097

Group type: EXPERIMENTAL
Intervention: Three-session medical education program on structured hypertension management for general practitioners.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 24
Study: 23218998

Group type: COMPARATOR
Intervention: 7 hours of sleep (reference group)
Number of subjects: 18755

Group type: EXPERIMENTAL
Intervention: Lowest category of sleep duration
Number of subjects: 18755

Group type: EXPERIMENTAL
Intervention: Greatest category of sleep duration
Number of subjects: 18755

Group type: EXPERIMENTAL
Intervention: Greatest category of sleep duration with prevalent sleep apnea
Number of subjects: 18755

Group type: EXPERIMENTAL
Intervention: Lowest category of sleep duration with prevalent sleep apnea
Number of subjects: 18755

Group type: EXPERIMENTAL
Intervention: Greatest category of sleep duration without sleep apnea
Number of subjects: 18755

Group type: EXPERIMENTAL
Intervention: Lowest category of sleep duration without sleep apnea
Number of subjects: 18755
Study: 21114549

Group type: EXPERIMENTAL
Intervention: 75 mg/kg karaya saponin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 25 mg/kg karaya saponin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: karaya saponin (various doses)
Number of subjects: 80
Study: 18165565

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketamine 0.75 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Meperidine 25 mg
Number of subjects: 90
Study: 16488054

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m2 on days 1 and 8 plus cisplatin 75 mg/m2 on day 1
Number of subjects: 83

Group type: COMPARATOR
Intervention: Etoposide 100 mg/m2 on days 1-3 plus cisplatin 75 mg/m2 on day 1
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Number of subjects: 83

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin
Number of subjects: 83
Study: 14673011

Group type: EXPERIMENTAL
Intervention: methylphenidate (0.5 mg/kg, i.v.)
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 11036120

Group type: EXPERIMENTAL
Intervention: Lipoprotein‐associated phospholipase A2
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: C‐reactive protein
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: White‐cell count
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Fibrinogen levels
Number of subjects: 580

Group type: COMPARATOR
Intervention: Control group (no coronary event)
Number of subjects: 580
Study: 9377844

Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 18
Study: 8412414

Group type: EXPERIMENTAL
Intervention: 15 mg d-fenfluramine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30 mg d-fenfluramine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30 mg l-fenfluramine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 50 mg chlorpromazine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3321394

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29476933

Group type: EXPERIMENTAL
Intervention: Corrective Exercise Continuum (CEC) program for 16 weeks
Number of subjects: 28
Study: 26756518

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 124

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 124

Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 124
Study: 25646929

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 600 mcg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Laminaria
Number of subjects: 84
Study: 23298079

Group type: EXPERIMENTAL
Intervention: Hydrogel injection
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Automated treatment planning using predicted doses from OVH
Number of subjects: 21

Group type: COMPARATOR
Intervention: Manual treatment planning (control)
Number of subjects: 21
Study: 20205482

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (SGLT2 inhibitor)
Number of subjects: 0
Study: 18155037

Group type: EXPERIMENTAL
Intervention: Economic intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care for orphans
Number of subjects: 96
Study: 15889312

Group type: EXPERIMENTAL
Intervention: Supervised and home-based impact exercise training
Number of subjects: 160

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 160
Study: 12802837

Group type: EXPERIMENTAL
Intervention: Self-administered medication program
Number of subjects: 350

Group type: COMPARATOR
Intervention: Nurse-administered medications
Number of subjects: 350
Study: 10373999

Group type: EXPERIMENTAL
Intervention: Usual care plus telephone counselling (intervention group)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 396
Study: 8558208

Group type: EXPERIMENTAL
Intervention: 0.6 mg ibandronate
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 1.1 mg ibandronate
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 2.0 mg ibandronate
Number of subjects: 174
Study: 1757027

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronic acid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hydroxypropylmethyl cellulose (HPMC)
Number of subjects: 200
Study: 6625031

Group type: EXPERIMENTAL
Intervention: Richmond/Hopkins Family Coping Index with revised operational guidelines
Number of subjects: 0
Study: 30982776

Group type: EXPERIMENTAL
Intervention: Telemedicine (internet-based video counseling)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (standard face-to-face clinical visit)
Number of subjects: 115
Study: 28145842

Group type: EXPERIMENTAL
Intervention: Otoscopy Simulation (OS)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Web-Based Module (WM)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard Instruction (SI)
Number of subjects: 54
Study: 27087080

Group type: EXPERIMENTAL
Intervention: Plantago ovata husk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24889138

Group type: EXPERIMENTAL
Intervention: Figure 8 FlatWire
Number of subjects: 63

Group type: COMPARATOR
Intervention: Steel wire cerclage
Number of subjects: 63